Rising Incidence of Diabetes in Children Amidst COVID-19: A Comprehensive Analysis

By HEOR Staff Writer

July 28, 2023

The COVID-19 pandemic has had far-reaching implications, with recent reports indicating a surge in the incidence of pediatric diabetes. To gain a clearer understanding of this association, a systematic review and meta-analysis of various studies published in English was conducted. 

The analysis included 42 studies, covering 102,984 incident diabetes cases. The results revealed a significant increase in the incidence rate of type 1 diabetes and diabetic ketoacidosis (DKA) in children and adolescents during the first two years of the pandemic compared to the pre-pandemic period. 

While the exact mechanism linking COVID-19 to the onset of diabetes remains unclear, potential factors might include lifestyle changes, stress, social isolation, and disruptions in healthcare access due to pandemic containment measures. 

These findings underscore the urgent need for increased resources and support for the growing number of children and adolescents with diabetes.  Future studies are required to determine whether this trend continues, and to shed light on the possible underlying mechanisms explaining these temporal changes. 

 

The increased incidence of DKA at diagnosis highlights the need to identify gaps in the pathway from the onset of diabetes symptoms to diagnosis. This information is crucial for developing effective strategies to prevent DKA at diagnosis in children. 

 

 

Reference url

Recent Posts

Merck Q1 2026 Performance: Growth and Innovations in Oncology and Cardiometabolic Care

By HEOR Staff Writer

April 30, 2026

Merck’s first-quarter 2026 results have been published and highlight key growth drivers, regulatory achievements, and strategic moves that reinforce the company’s diversified portfolio. Oncology Dominance Fueled by KEYTRUDA Expansion Merck Q1 2026 performance was prima...
Advancing High-Risk Oncology Interventions: Promising Developments from ASCO 2026
Johnson & Johnson is driving progress in high-risk oncology interventions through more than 20 clinical and real-world studies presented at the 2026 ASCO Annual Meeting. By focusing on earlier therapeutic intervention and precision regimens, the company aims to improve outcomes in prostate ca...
Establishing a Vaccine Confidence Strategy: EMA’s New Advisory Group Tackles Public Health ...
The European Medicines Agency (EMA) has introduced a dedicated vaccine confidence strategy through the launch of a new advisory group. Comprising more than 20 high-level experts from academia, healthcare, patient organisations, and public health bodies, the group held its first meeting on 29 Apri...